Search: onr:"swepub:oai:lup.lub.lu.se:a8416386-ad1a-470a-87dc-aa039af2033a" > Interval breast can...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05382naa a2200505 4500 | |
001 | oai:lup.lub.lu.se:a8416386-ad1a-470a-87dc-aa039af2033a | |
003 | SwePub | |
008 | 220228s2022 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:149687968 | |
024 | 7 | a https://lup.lub.lu.se/record/a8416386-ad1a-470a-87dc-aa039af2033a2 URI |
024 | 7 | a https://doi.org/10.1016/j.ejca.2021.12.0032 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1496879682 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Ugalde-Morales, Emiliou Karolinska Institutet,Karolinska Institute4 aut |
245 | 1 0 | a Interval breast cancer is associated with interferon immune response |
264 | 1 | b Elsevier BV,c 2022 |
300 | a 12 s. | |
520 | a Background: The aggressive nature of breast cancers detected between planned mammographic screens, so-called interval cancers, remains elusive. Here, we aim to characterise underlying molecular features of interval cancer. Methods: From 672 patients with invasive breast cancer, we analysed gene expression differences between 90 ‘true’ interval cancer cases (i.e. women with low-dense breasts defined as per cent mammographic density <25%) and 310 screen-detected tumours while accounting for PAM50 subtypes and thus overall tumour aggressiveness. We computed an interval cancer gene expression profile (IC-Gx) in a total of 2270 breast tumours (regardless of interval cancer status) and tested for association with expression-based immune subtypes in breast cancer. In addition, we investigated the contribution of inherited and somatic genetic variants in distinct features of interval cancer. Results: We identified 8331 genes nominally associated with interval cancer (P-value < 0.05, fold-change > 1.5). Gene set enrichment analysis showed immune-related pathways as key processes altered in interval cancer. Our IC-Gx, based on 47 genes with the strongest associations (false discovery rate < 0.05), was found to be associated mainly with immune subtypes involving interferon response. We isolated an interaction network of interval cancer and interferon genes for which a significant load of somatic and germline variants in class I interferon genes was observed. Conclusion: We identified novel molecular features of interval breast cancer highlighting interferon pathways as a potential target for prevention or treatment. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Interferon immune response | |
653 | a Interval breast cancer | |
653 | a Mammographic density | |
653 | a PAM50 subtypes | |
700 | 1 | a Grassmann, Felixu Karolinska Institutet,Karolinska Institute,Health and Medical University4 aut |
700 | 1 | a Humphreys, Keithu Karolinska Institutet,Karolinska Institute4 aut0 (Swepub:lu)med-khu |
700 | 1 | a Li, Jingmeiu Karolinska Institute,National University of Singapore,A*Star, Genome Institute of Singapore (GIS)4 aut |
700 | 1 | a Eriksson, Mikaelu Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Tobin, Nicholas P.u Karolinska Institutet,Karolinska Institute4 aut0 (Swepub:lu)med-npt |
700 | 1 | a Lindström, Linda S.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Vallon-Christersson, Johanu Lund University,Lunds universitet,Create Health,Annan verksamhet, LTH,Lunds Tekniska Högskola,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Other operations, LTH,Faculty of Engineering, LTH,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)onk-jvc |
700 | 1 | a Borg, Åkeu Lund University,Lunds universitet,Create Health,Annan verksamhet, LTH,Lunds Tekniska Högskola,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Familjär bröstcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Other operations, LTH,Faculty of Engineering, LTH,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Familial Breast Cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)onk-abo |
700 | 1 | a Hall, Peru Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Czene, Kamilau Karolinska Institutet,Karolinska Institute4 aut |
710 | 2 | a Karolinska Institutetb Karolinska Institute4 org |
773 | 0 | t European Journal of Cancerd : Elsevier BVg 162, s. 194-205q 162<194-205x 0959-8049x 1879-0852 |
856 | 4 | u http://dx.doi.org/10.1016/j.ejca.2021.12.003x freey FULLTEXT |
856 | 4 | u http://www.ejcancer.com/article/S0959804921012582/pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/a8416386-ad1a-470a-87dc-aa039af2033a |
856 | 4 8 | u https://doi.org/10.1016/j.ejca.2021.12.003 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:149687968 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.